Savara Inc. announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, scheduled for September 27 – October 1, in Amsterdam, The Netherlands. The company will also host an Industry Evening Mini Symposium at the meeting.
New data from the Phase 3 IMPALA-2 clinical trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) will be presented. These presentations will focus on the relationship between pulmonary gas transfer, respiratory health-related quality of life, exercise capacity, and surfactant burden.
Additionally, data on the efficacy of inhaled molgramostim according to the severity of aPAP will be shared. Savara's partner, TrilliumBiO, will also present data on the development of a dried blood spot test to aid in the diagnosis of aPAP.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.